Intriguingly, ActRIIB-Fc can block both activin A as well as myostatin [23], that could potentially be very beneficial in conditions, such as frailty and DMD, which involve both muscle and bone [9]. This evidence concerns the gene ACVR2B and Duchenne muscular dystrophy.